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Introduction
Gastrointestinal stromal tumor (GIST) is the most common 
mesenchymal tumor of the gastrointestinal tract, afflicting an 
estimated 3000 to 6000 new patients each year.1 It typically pres-
ents between the fifth and sixth decade of life with abdominal 
pain, symptoms of anemia or acute bleeding. Management of the 
disease has been transformed by the identification of activating 
mutations in the tyrosine kinase receptors, KIT and PDGFRA, 
leading to the unprecedented disease control of advanced GIST 
with the introduction of the kinase inhibitors imatinib mesyl-
ate (IM), sunitinib malate, and regorafenib. Response to treat-
ment has been correlated with the site of the mutation in KIT or 
PDGFRA, with those tumors carrying mutations in exons 11 and 
12, respectively, having the best response to therapy.2 The success 
of IM in GIST has been tempered by the fact that treatment in the 
advanced disease setting only increases the median time to tumor 
progression by approximately 2 y. Reasons identified for this lim-
ited therapeutic efficacy include decreased effectiveness of IM for 
KIT mutations outside of exon 11 and in tumors lacking muta-
tions in KIT and PDGFRA. Furthermore, GISTs that progress 
are likely to have secondary mutations in KIT or PGDFRA and/
or epigenetic changes that act together to create a more aggressive 
tumor. Sunitinib therapy offers a median of an additional 5 mo 
delay to tumor progression3 and is currently used as the second-
line therapy. Regorafenib, FDA approved in February 2013, is 
now the third-line drug of choice with a median progression free 
survival (PFS) of 4.8 mo.4,5 However, it is clear that additional 
therapies are still needed and methods to optimize screening of 
novel approaches are warranted.
In clinical trials, efficacy of therapies is measured utilizing 
RECIST criteria, a measure of change in tumor size over time 
using clinical imaging technologies (CT, MRI). RECIST, which 
looks at tumor size only, has been critiqued as not correlating with 
clinical improvement, metabolic response by [18F] fluorodeoxy-
glucose-positron emission tomography (FDG-PET), or patho-
logic response. For example, patients with IM-treated tumors 
that remain stable in size have similar survival to those with 
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Gastrointestinal stromal tumors (GIsTs) are the most common mesenchymal tumors in the Us. The majority (~85%) 
of GIsTs possess gain-of-function mutations in KIT or PDGFRA, causing constitutive activation of the kinase receptor. GIsT 
management has been transformed by the identification of tumor driver mutations leading to unprecedented disease 
control of advanced GIsT with the introduction of imatinib mesylate (IM). Despite IM’s efficacy, most patients experience 
primary and/or secondary resistance within 2 y of treatment. additional therapies and methods to optimize screening of 
novel approaches in preclinical studies are warranted. clinically, treatment efficacy is typically assessed using Response 
evaluation criteria In solid Tumors (RecIsT) guidelines or choi criteria. Both require a period of time on therapy before 
changes indicative of response can be observed. In addition, neither informs directly about cell death. We evaluated the 
use of molecular imaging technology in an animal model using near-infrared (NIR) imaging probes together with three-
dimensional fluorescence molecular tomography (FMT) for assessing therapeutic response and ultimately optimizing 
our understanding of the biologic effects of these agents. We determined the potential of NIR probes (PsVueTM794 and 
cell-penetrating KcapQ647) for detecting distinct markers of apoptosis and compare this to tumor size measured by MRI 
in response to IM treatment in GIsT-T1 xenografts. Our studies revealed statistically significant increases in apoptosis due 
to IM treatment using both probes as early as 24 h post IM treatment which was confirmed by Ihc. Molecular imaging will 
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documented tumor response. FDG-PET metabolic response has 
predicted RECIST response. The Choi criteria defines treatment 
response as a >10% decrease in tumor size or a >15% decrease 
in tumor density of tumor lesions assessed on contrast-enhanced 
CT (CT) scans. Response by Choi criteria has been shown to cor-
relate better with FDG-PET than standard RECIST response.6
A better understanding of imaging as it correlates with biologic 
markers of response is needed; imaging that informs researchers 
and clinicians more directly about cell death may be superior to 
current techniques. IM has been previously shown to cause apop-
tosis in vitro in IM-sensitive cell lines.7-10 Therefore, in this study 
we sought to evaluate the use of molecular imaging technology 
using near-infrared (NIR) imaging probes in combination with 
three-dimensional fluorescence molecular tomography (FMT) 
for assessing therapeutic response and ultimately improving our 
understanding of the biologic effects of these agents. Here, using 
GIST-T1 xenografts, we evaluate the potential of two NIR probes 
detecting two distinct markers of early apoptosis and compare 
this to tumor size measured by magnetic resonance imaging 
(MRI) in response to IM treatment.
Results
To develop methods for assessing novel therapeutic agents 
or combinations of agents to effectively treat GIST, we sought 
to evaluate whether we could successfully visualize treatment-
related apoptosis in GIST xenografts using a treatment known 
to be effective both clinically and in this model. To do this, we 
utilized three NIR probes: IntegriSense680, PSVueTM794, and 
KcapQ647, in combination with FMT imaging. In preliminary 





, localized strongly and specifically 
to the GIST xenograft tumors and could therefore be used to 
determine the three dimensional region of interest (ROI) in the 
FMT data sets. This was necessary because the signal from the 
apoptosis sensing probes was not as strong, and did not localize 
as specifically to the tumors as the IntegriSense680 probe. The 
time for optimal imaging (maximum signal in the tumor as com-
pared with the whole-body background) for the IntegriSense680 
probe was determined to be 96 h post-injection. We then per-
formed additional preliminary studies using the PSVueTM794 
and KcapQ647 NIR probes, in separate studies, to determine 
optimal time points for imaging following probe injection by 
acquiring longitudinal images. To do this, 8 mice with GIST-T1 
cell xenografts (4 vehicle and 4 IM-treated) were given retro-
orbital injections of either PSVueTM794 or KcapQ647 in combi-
nation with IntegriSense680. FMT Images were acquired at 0.5, 
1, 3, 6, 12, 18, and 24 h post-probe injection. With both probes, 
all IM-treated GISTs had significantly more probe signal than 
vehicle-treated tumors at both 24 h post-IM treatment (Fig. 1) 
as well as 1 wk post-treatment, with the optimal imaging times 
of 18 h post-injection for PSVueTM794 and 1 h post-injection for 
KcapQ647. Following these pilot studies, a larger cohort of mice 
(n = 14) bearing GIST-T1 xenografts were randomized into two 
treatment groups: vehicle and IM. These mice were injected with 
all three probes (IntegriSense680, PSVueTM794, KcapQ647) 
at the previously determined optimal imaging times, and were 
treated with vehicle or IM (50 mg/kg daily). Twenty-four hours 
post treatment, all mice were imaged in the 645, 680, and 750 
nm channels to determine individual probe retention in the 
tumor. This imaging schedule was repeated in these mice one 
week post treatment. To improve the power to detect a difference 
between vehicle and IM treated animals, we combined this data 
with data from both aforementioned studies. As outlined earlier, 
the GEE methodology was used to model treatment effect and 
time on apoptotic activity, adjusted for potential batch effects in 
the experiment. A statistically significant increase in the rate of 
apoptotic activity due to IM treatment (compared with control) 
was observed (P value = 0.002) using data from the KcapQ647 
probe. However, there was neither a significant change in apop-
totic activity with time (P value = 0.69) nor treatment effect with 
time (P value = 0.41). Similarly, a statistically significant increase 
in the rate of apoptotic activity due to IM treatment (compared 
with control) was observed (P value = 1.41e−04) using data from 
the PSVueTM794 probe. Again, there was neither a significant 
change in apoptotic activity with time (P value = 0.11) nor treat-
ment effect with time (P value = 0.21). Figure 2A and B dis-
play the growth curves for the IM treated and vehicle treated 
control groups based on data obtained using the KcapQ647 and 
PSVueTM794 probes, respectively. It is evident that IM treat-
ment increases apoptotic activity (as measured by both probes) 
compared with vehicle-treated control at each time point (days 
1 and 7) (Fig. 2C and D). Vehicle treatment on day seven shows 
elevated PSVueTM794 retention compared with that on day one 
(Fig. 2C). This is most likely explained by the mechanism of 
the probe. PSVueTM794 probe works by targeting phosphatidyl-
serines exposed on the cell surface of apoptotic cells; however, 
this probe cannot distinguish between apoptotic and necrotic 
cell membranes in vivo. KcapQ647, a caspase-activatable probe, 
allows for better discernment between apoptosis and necrosis. 
Therefore, the increased PSVueTM794 signal in vehicle treated 
tumors after 1 wk is most likely attributable to necrosis occur-
ring in these tumors as they grow larger. As measured by the 
KcapQ647 probe, treatment with IM shows decreased signal on 
day 7 compared with that on day 1, while the PSVueTM794 probe 
shows an increase in signal, again most likely a combination of 
both apoptosis and necrosis detected by PSVueTM794 in these 
tumors, with no significant change over time (Fig. 2C and D).
Immediately following FMT imaging, we performed MRI 
scans to measure tumor volume. Due to the often flat and irregular 
morphology of these GIST-T1 xenografts (Fig. 3A, white arrow), 
we previously have found MRI tumor volume measurements to 
be more precise than standard caliper measurements, and our 
rapid MRI scanning protocol permits an efficient and cost effec-
tive method for obtaining these data. Not surprisingly, 24 h after 
IM treatment no tumor shrinkage was observed in the IM-treated 
cohort relative to their vehicle-treated counterparts (Fig. 3B, mid-
dle plot). These findings highlight the advantage of using the NIR 
probes in combination with FMT imaging to detect apoptosis at 
earlier time points, not possible with MRI, caliper measurements, 
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Figure 1. Detection of GIsT with Integrisense680 and treatment-related apoptosis with KcapQ647. Representative images of FMT imaging of GIsT 
xenografts treated with vehicle (top panel) or with IM (50 mg/kg) for 24 h (bottom panel). Images on the left are 2D reflectance images, in the middle, 
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post-treatment, a trend toward treatment-related shrinkage was 
observed by MRI (Fig. 3B, third plot; Fig. 3C).
Finally, to validate these in vivo findings, immunohistochem-
ical (IHC) analysis was performed ex vivo on tumors harvested 
from the mice upon conclusion of the one week post-treatment 
imaging. Tissue sections from all mice (n = 22) were stained for 
markers of apoptosis, cleaved Lamin A and cleaved Caspase-3. 
Histological examination demonstrated significant levels of both 
apoptotic markers in the mice treated with IM compared with 
their vehicle treated counterparts (Fig. 4).
Figure 2. Quantification of IM-related apoptosis using NIR probes with FMT imaging. change in apoptotic activity measured by the PsVueTM794 (A) and 
KcapQ647 (B) probes between day 1 and day 7 of treatment with IM or vehicle control. each measurement on apoptotic activity was normalized to its 
corresponding tumor volume measurement obtained using MRI and expressed as a ratio (on the log-scale). a longitudinal model based on the general-
ized estimating equations approach was used to model the effect of treatment and time on apoptotic activity, adjusted for potential batch effects in 
the experiment. statistically significant increases in the rate of apoptotic activity due to IM treatment (compared with control) was observed (P value 
= 1.41e−04 and 0.002, respectively) using data from the PsVueTM794 and KcapQ647 probes. Box-and-whisker plots of the apoptotic activity measured 
by the PsVueTM794 (C) and KcapQ647 (D) probes on the logarithmic scale for various treatment-time combinations. In each plot, box height represents 
the inter-quartile range (IQR) where the upper and lower ends indicate the third and first quartiles, respectively. The solid black horizontal line inside 
the box represents the median value while the whiskers (the two solid horizontal lines at either end, connected by dotted lines) extend to the most 
extreme data points which are no more than 1.5 times the IQR from the box in each direction. Using this criterion, points that lie beyond these whiskers 
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Discussion
Since the FDA approval of IM in 2002, the treatment of 
GIST has radically improved. Advanced GIST, resistant to stan-
dard chemotherapy and radiation, can now be controlled initially 
with IM in the majority of cases. However, these effects are often 
short-lived, with IM demonstrating a median time to progression 
of approximately 2 y. More recently, sunitinib and regorafenib 
have been approved for second- and third-line options, though 
both have PFS of less than 6 mo. In addition, there are currently 
greater than 15 investigational agents being evaluated for the 
management of GIST, including a number of small molecule 
inhibitors of Hsp90 and IGF1R.11 With this wealth of agents 
currently being investigated as well as the fact that researchers are 
actively seeking out novel targets in GIST, it is becoming increas-
ingly obvious that preclinical testing of these agents and/or novel 
combinations of agents will be essential in discovering optimal 
treatment regimens for GIST patients that have failed on the first 
three lines of treatment.
Much of the effort, to date, involving preclinical evalua-
tion of therapeutics in vivo for GIST has consisted of imaging 
using small animal FDG-PET.12-16 Cullinane and colleagues 
(2005) demonstrated, in a xenograft model using FDC-P1 cell 
lines expressing either an IM-sensitive or -resistant KIT muta-
tion, that IM led to a rapid reduction in FDG uptake on PET as 
early as 4 h post-treatment in the IM-sensitive model.15 In 2010, 
Revheim et al.14 showed decreased tumor-to-liver uptake ratios in 
GIST xenografts 1 d and 8 d post-treatment with both IM and 
sunitinib using a clinical PET/CT. Additionally, Pantaleo et al. 
(2010) preclinically evaluated two additional small molecule 
inhibitors, nilotinib and everolimus, in a GIST xenograft model, 
as single agents or in combination with IM, using FDG-PET 
imaging.13 This study demonstrated that all three single agents 
led to decreased glucose uptake at 4 and 13 d post-treatment, 
with the combination of IM and everolimus being superior to 
all other treatment arms. Most recently, Floris and colleagues 
demonstrated the successful combination of the PI3K inhibi-
tor, GDC-0951, and IM in GIST xenografts using micro-PET 
Figure 3. Treatment-associated tumor shrinkage is not evident 24 h post IM treatment. (A) MR image showing GIsT-T1 xenograft. (B) Box-and-whisker 
plots of tumor volume (mm3) measured 7 d prior to treatment (first plot), 1 d post-IM treatment (middle plot), and 7 d post-IM treatment by MRI (last 
plot). (C) comparison of tumor volume change from 1 d post-treatment to 1 wk post-treatment between IM and vehicle-treated groups. P value is 0.094 
using the Mann–Whitney test comparing the two differences IM day 7 − IM day 1 and vehicle day 7 − vehicle day 1. In all box plots, box height represents 
the inter-quartile range (IQR) where the upper and lower ends indicate the third and first quartiles, respectively. The solid black horizontal line inside 
the box represents the median value while the whiskers (the two solid horizontal lines at either end, connected by dotted lines) extend to the most 
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imaging.16 An alternative approach has recently been reported 
using a fluorophore-conjugated anti-KIT antibody imaged by 
fluorescence laparoscopy to detect and visualize cecal GISTs in 
KIT K641E+/− transgenic mice.17 This approach yielded an accu-
racy of 92% in tumor detection and the authors speculate that 
this method has future potential in disease response as well as 
staging, evaluating tumor margin status, and identifying perito-
neal metastases. It should be noted however, that the use of FDG 
PET or the labeled anti-KIT antibody do not assess apoptosis of 
cells.
Our study is a proof of concept demonstrating that in vivo 
molecularly targeted imaging can be successfully used to evaluate 
preclinical therapies non-invasively in GIST xenograft models. 
We successfully show that two NIR probes, PSVueTM794 and 
KcapQ647, can be used to quantify levels of apoptosis, as early 
as 24 h post-IM treatment. These probes have varying mecha-
nisms of action with PSVueTM794 targeting phosphatidylserines 
exposed on the cell surface of both apoptotic and necrotic cells 
membranes, whereas the cell-penetrating probe, KcapQ647, 
possesses a cleavable domain (DEVD), a specific substrate for 
caspase-3, that therefore can better distinguish apoptotic from 
necrotic cells. KcapQ647 also has the advantage of a rapid and 
potentially translatable optimal imaging time (1 h post injection) 
compared with the other probes. Even with different mechanisms, 
both probes were able to detect IM-related apoptosis, which was 
subsequently confirmed by IHC staining of both cleaved Lamin 
A and cleaved caspase-3. This approach is superior to standard 
caliper tumor volume measurements, CT or MRI images, all of 
which are commonly used in the GIST preclinical setting as a 
readout of therapeutic efficacy, since this methodology allows for 
rapid detection of cell death in response to drug. In addition, 
we believe that this technology can be used preclinically as an 
alternative to PET imaging to avoid the use of radionuclides and 
to look at the effects of novel therapeutic agents or combination 
of agents at the molecular level. We hypothesize that using this 
non-invasive approach in preclinical models of GIST has poten-
tial in evaluating new agents, combination of agents or varying 
doses and dosing schedules and could allow us to assess the need 
to change treatment regimens or discontinue their development 
much earlier, when we see that there is no apoptosis induced by 
the investigational therapy. Future studies evaluating novel ther-
apies are planned to test this hypothesis.
Methods
GIST xenografts and drug administration
All studies involving animals followed procedures approved 
by the Fox Chase Cancer Center Institutional Animal Care and 
Use Committee. GIST-T1 cells, a tumor cell line possessing a het-
erozygous mutation in KIT exon 11 kindly provided by Takahiro 
Taguchi,18 were washed and subsequently resuspended in phos-
phate-buffered saline (PBS) at a density of 3 × 106 cells/100 μL. 
One hundred microliters of cells in PBS were mixed thoroughly 
with 100 μL MatrigelTM Matrix (BD Biosciences) and the sus-
pension was injected subcutaneously into the right flanks of 
athymic nude mice (strain NCRNU, Taconic Inc.). Mice were 
maintained on a standard diet (2018SX Teklad Global; Harlan 
Laboratories) and transitioned to a purified, alfalfa-free rodent 
chow (Teklad AIN76A; Harlan Laboratories) for a minimum of 
48 h before imaging to minimize fluorescence in the gut, as well 
as drinking water ad libitium. Tumor volumes were measured 
twice weekly by MRI. When tumors reached approximately 
300 mm3, mice were randomized into two groups. One group 
was administered IM orally at 50 mg/kg daily and the second 
group received only vehicle (sterile water).
Near-infrared fluorescent optical imaging agents





detecting tumor-associated integrin receptor expression was uti-
lized to determine tumor regions of interest (ROI).19 PSVueTM794 
(Molecular Targeted Technologies), used as a marker of apop-
tosis, binds to phosphatidylserine residues exposed on the cell 
surface of apoptotic cells and, in addition, binds to negatively-
charged necrotic regions found in various tumors through its zinc 
(II)-dipicolylamine (Zn-DPA).20,21 A third probe, KcapQ647 
(synthesized in the laboratory of Dr. David Piwnica-Worms), a 
cell-penetrating activatable probe was used to detect apoptosis-
associated caspase activity.22-24
Magnetic resonance imaging
To accurately determine tumor volume, mice were imaged in 
a 7 Tesla Vertical bore MRI system with a Bruker DRX spec-
trometer and Paravision 3.0.1 software. A T2 weighted RARE 
(rapid acquisition of refocused echoes) pulse sequence provided 
rapid imaging times and good delineation of tumor margins. 
Twenty-six slices were acquired with MRI acquisition param-
eters: T
R
 = 2300 msec, T
E
 = 8.8 msec, rare factor = 8, effective 
T
E
 = 36.8 msec, nex = 2, slice thickness = 1 mm, field of view = 
2.56 mm, acquisition matrix = 256 × 256, and imaging time of 
2.5 min. During imaging, animals were anesthetized with 2% 
isoflurane in O
2
. The total time to image one mouse, including 
Figure  4. IM treatment causes higher levels of apoptotic mark-
ers, cleaved caspase-3 and cleaved Lamin a, in GIsT xenografts. 
Immunohistochemistry of GIsT-T1 xenografts, treated with vehicle (left 
column) or with IM (right column) for one week, for cleaved caspase-3 
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animal preparation, was less than 10 min. Tumor volume was 
measured with the Paravision 3.0 software by manually outlining 
the tumor on each image slice where it appeared, and then sum-
ming the volumes from the individual slices. Because the subcu-
taneous tumors tended to have a relatively flat morphology, we 
found the MRI measurements to be superior to estimating tumor 
volume with calipers.
Fluorescence-molecular tomography (FMT)
In vivo FMT was performed with the VisEn FMT2500 
Quantitative Tomography Imaging System (Perkin Elmer Inc. 
Waltham, MA). FMT imaging was performed according to the 
manufacturer’s standard procedures. Mice were anesthetized 
with isoflurane (2% in O
2
), and placed in the bi-planar imaging 
cassette supplied with the FMT2500. Mice were imaged in the 
645 nm (KcapQ647), 680 nm (Integrisense680), and 750 nm 
(PSVueTM794) channels. The FMT imaging times were of approx-
imately 15 min duration for each mouse. Transmission and fluo-
rescence images were captured with a thermo-electrically cooled 
CCD camera. Three-dimensional volumetric FMT image sets 
were reconstructed to an isotropic spatial resolution of 1 mm3, and 
displayed with the TrueQuantTM software package supplied with 
the FMT2500. A small dose (0.5 nmoles, approximately ¼ the 
standard dose of 2 nmoles) of Integrisense680 (Perkin-Elmer) was 
injected 96 h prior to imaging to mark the tumor position. Prior 
work had indicated that in this model Integrisense680 imaged at 
this time provided very accurate delineation of the tumors, with 
very little background in the rest of the mouse. PSVueTM794 was 
injected 18 h and KcapQ647 1 h prior to imaging. All probes 
were injected retro-orbitally with an injection volume of 0.1 mL. 
Images were analyzed with the Truquant software supplied with 
the FMT imaging system.
Tissue preparation and immunohistochemical analysis
Upon conclusion of imaging, mice were euthanized by CO
2
 
asphyxiation and tumors were harvested, fixed in 10% forma-
lin overnight, and embedded in paraffin. GIST tumors were 
confirmed by staining with hematoxlyin and eosin (H&E) 
as well as CD117 (KIT, DAKO). Apoptosis was assessed using 
antibodies recognizing cleaved Lamin A and cleaved Caspase-3 
(Cell Signaling Technology). Immunohistochemical staining was 
performed on 5 μm slides. After deparaffinization and rehydra-
tion, sections were subjected to heat-induced epitope retrieval by 
immersion in a 0.01 M citrate buffer (pH 6.0). Endogenous per-
oxidase activity was blocked for 15 min in 3% hydrogen perox-
ide in methanol. Nonspecific binding was blocked by treatment 
with a blocking reagent (Protein Block Serum-Free, DAKO) for 
30 min at room temperature. The slides were then incubated over-
night with primary antibody at 4 °C in a humidified chamber. 
Immunodetection was performed by using the Sensitive™ Link-
Label (Biotin-based) IHC Detection Systems.
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